Tecentriq-H-C-PSUSA-00010644-202305: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Advanced pharmaceutical formulation for targeted therapeutic intervention.
Source
European Medicines Agency
Additional Information
medication.label.product_type
scientific-conclusion
medication.label.permit_number
EMA/130056/2024
medication.label.permit_validity
First published: 2024-03-25T14:07:21Z
Documents
Related Medications
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
AI Voice
Listen to the article content live